TABLE 1.
VSV-neutralizing antibody responses
| Vaccination strategy | Vaccinea
|
Rabbit no. | Neutralizing antibody titer to VSV (relative to time of immuniation)d
|
||||
|---|---|---|---|---|---|---|---|
| Primary (PFU, 5 × 105) | Booster (PFU, 1 × 107) | wk 3 | wk 5 | wk 7-8 | wk 10-13 | ||
| Expt 1 | VSV-GFP (i.n.) | 1 | 1:4,096 | 1:4,096 | 1:8,192 | 1:8,192 | |
| 2 | 1:1,024 | 1:2,048 | 1:2,048 | 1:2,048 | |||
| 3 | 1:2,048 | 1:4,096 | 1:4,096 | 1:16,384 | |||
| 4 | 1:4,096 | 1:1,024 | 1:4,096 | 1:2,048 | |||
| 5 | 1:1,024 | 1:1,024 | 1:2,048 | 1:2,048 | |||
| VSV-L1 (i.n.)b | 6 | 1:2,048 | 1:2,048 | 1:2,048 | 1:8,192 | ||
| 7c | — | — | — | — | |||
| 8 | 1:2,048 | 1:1,024 | 1:2,048 | 1:16,384 | |||
| 9 | 1:128 | 1:256 | 1:512 | 1:512 | |||
| 10 | 1:1,024 | 1:512 | 1:2,048 | 1:8,192 | |||
| Expt 2 | VSV-L1 (i.d.) | VSV-L1 (i.d.) | 1 | ND | 1:256 | 1:256 | 1:1,024 |
| 2 | ND | 1:512 | 1:1,024 | 1:4,096 | |||
| 3 | ND | 1:512 | 1:512 | 1:8,192 | |||
| VSV-L1 (i.n.) | VSV-L1 (i.n.) | 4 | ND | — | — | 1:1,024 | |
| 5 | ND | 1:128 | 1:128 | 1:2,048 | |||
| 6 | ND | 1:1,024 | 1:512 | 1:4,096 | |||
| VSV-L1 (i.m.) | VSV-L1 (i.m.) | 7 | ND | 1:256 | 1:128 | 1:8,192 | |
| 8 | ND | 1:256 | 1:256 | 1:8,192 | |||
| 9 | ND | 1:1,024 | 1:512 | 1:8,192 | |||
| VSV-L1 (i.vag.) | 10 | ND | — | — | — | ||
| 11 | ND | — | — | — | |||
| 12 | ND | — | — | — | |||
a
i.n., intranasal; i.d., intradermal; i.m., intramuscular; i.vag., intravaginal.
b
All rabbits in this group were given 10 μg of denatured L1 protein intradermally at 7 weeks postvaccination.
c
Rabbit was administered a boost of VSV-L1 at 5 weeks due to failure of the primary vaccination.
d
—, VSV-neutralizing antibody titer < 1:8; ND, not done. Postboost neutralization titers are in boldface. Preimmunization titers were all <1:8.